sk&f 86002 has been researched along with Sarcoma, Kaposi in 2 studies
6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase
Sarcoma, Kaposi: A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bender Ignacio, RA | 1 |
| Lee, JY | 1 |
| Rudek, MA | 1 |
| Dittmer, DP | 1 |
| Ambinder, RF | 1 |
| Krown, SE | 1 |
| Sodhi, A | 1 |
| Montaner, S | 1 |
| Patel, V | 1 |
| Zohar, M | 1 |
| Bais, C | 1 |
| Mesri, EA | 1 |
| Gutkind, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Trial of PTC299 in Patients With HIV-Related Kaposi's Sarcoma[NCT00686842] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Drug supply unavailable.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients who experienced an adverse event of grade 3 or greater (NCT00686842)
Timeframe: All study visits
| Intervention | participants (Number) |
|---|---|
| VEGF Inhibitor PTC299 | 7 |
1 trial available for sk&f 86002 and Sarcoma, Kaposi
| Article | Year |
|---|---|
Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; DNA, Viral; Enzyme | 2016 |
1 other study available for sk&f 86002 and Sarcoma, Kaposi
| Article | Year |
|---|---|
The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha.
Topics: 3T3 Cells; Animals; Calcium-Calmodulin-Dependent Protein Kinases; COS Cells; DNA-Binding Proteins; E | 2000 |